Peginterferon beta-1a
Medication
From Wikipedia, the free encyclopedia
Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis.[4][5]
| Clinical data | |
|---|---|
| Trade names | Plegridy, Plegridy Pen |
| Other names | BIIB-017 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a614059 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Subcutaneous injection |
| Drug class | Antineoplastic agent |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C913H1417N246O256PS7 [C2H4O]n |
| Molar mass | 44000 g·mol−1 |
The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site.[4][5]
Peginterferon beta-1a was approved for medical use in the United States and in the European Union in 2014.[6][5]
Medical uses
In the United States, peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.[4]
In the European Union, peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults.[5]
